{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:13:48Z","timestamp":1793978028533,"version":"4.8.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thyroid eye disease is an autoimmune disorder of the orbital retrobulbar tissue commonly associated with dysthyroid status. The most frequent condition is hyperthyroidism, although it is also present in hypothyroid and euthyroid patients. The prevalence of thyroid conditions in patients with thyroid eye disease had been previously evaluated; however, there is no consensus on a global prevalence. The study aims to estimate the prevalence of hyperthyroidism, hypothyroidism, and euthyroidism in patients with TED, through a systematic review of literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review of the literature following the PRISMA guidelines, in MEDLINE, COCHRANE, EMBASE, Science Direct, and LILACS databases. Inclusion criteria were primary studies of patients with a diagnosis of thyroid eye disease made by an ophthalmologist or with diagnosis criteria, with measurement of thyroid function (TSH, T3, and free T4), and diagnosis of the primary thyroid condition. A quality assessment was made through the Joanna Briggs Institute Quality tools. Finally, we extracted relevant details about the design, the results, and the prevalence of thyroid disorders in thyroid eye disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The initial search revealed 916 studies, of which finally thirteen met inclusion criteria. Six studies were performed in Europe (Germany, Wales, and Spain), five in Asia (Iran, South Korea, Japan, and Singapore), one in North America (USA), and one in Africa (Ghana). The global prevalence, in patients of thyroid eye disease, was 10.36% for hypothyroidism, 7.9% for euthyroidism, and 86.2% for hyperthyroidism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Professionals should be aware that thyroid eye disease can be present in patients with a normal thyroid function. The assessment for these patients is based on orbital images; serum TSH, T3, and free T4; antibody levels as thyrotropin receptor antibodies; and thyroperoxidase levels. Additionally, we want to encourage research in this field in other regions of the world such as Latin America.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      PROSPERO ID\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=107167\">CRD42020107167<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13643-020-01459-7","type":"journal-article","created":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T14:27:50Z","timestamp":1598970470000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["Prevalence of hyperthyroidism, hypothyroidism, and euthyroidism in thyroid eye disease: a systematic review of the literature"],"prefix":"10.1186","volume":"9","author":[{"given":"Juliana","family":"Mu\u00f1oz-Ortiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Camila","family":"Sierra-Cote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefan\u00eda","family":"Zapata-Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Valenzuela-Vallejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Alejandra","family":"Marin-Noriega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Uribe-Reina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Terreros-Dorado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"G\u00f3mez-Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Arteaga-Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0684-1989","authenticated-orcid":false,"given":"Alejandra","family":"de-la-Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,1]]},"reference":[{"key":"1459_CR1","unstructured":"General Information\/Press Room [Internet]. American Thyroid Association. [cited 2020 Apr 7]. Available from: https:\/\/www.thyroid.org\/media-main\/press-room\/."},{"key":"1459_CR2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0953-6205(03)00101-8","volume":"14","author":"J Kvetny","year":"2003","unstructured":"Kvetny J. The significance of clinical euthyroidism on reference range for thyroid hormones. Eur J Intern Med. 2003;14:315\u201320.","journal-title":"Eur J Intern Med"},{"key":"1459_CR3","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0140-6736(16)00278-6","volume":"388","author":"S De Leo","year":"2016","unstructured":"De Leo S, Lee S, Braverman L. Hyperthyroidism. Lancet. 2016;388:906\u201318.","journal-title":"Lancet"},{"key":"1459_CR4","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0140-6736(17)30703-1","volume":"390","author":"L Chaker","year":"2017","unstructured":"Chaker L, Bianco AC, Jonklaas J, Peeters RP. Hypothyroidism. Lancet. 2017;390:1550\u201362.","journal-title":"Lancet."},{"key":"1459_CR5","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1056\/NEJM198302243080803","volume":"308","author":"GT Gamblin","year":"1983","unstructured":"Gamblin GT, Harper DG, Galentine P, Buck DR, Chernow B, Eil C. Prevalence of increased intraocular pressure in Graves\u2019 disease\u2014evidence of frequent subclinical ophthalmopathy. N Engl J Med. 1983;308:420\u20134.","journal-title":"N Engl J Med"},{"key":"1459_CR6","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","volume":"362","author":"RS Bahn","year":"2010","unstructured":"Bahn RS. Graves\u2019 ophthalmopathy. N Engl J Med. 2010;362:726\u201338.","journal-title":"N Engl J Med"},{"key":"1459_CR7","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1001\/archinte.1990.00390170124027","volume":"150","author":"MF Prummel","year":"1990","unstructured":"Prummel MF, Wiersinga WM, Mounts MP, Koornneef L, Berghout A, van der Gaag R. Effect of abnormal thyroid function on the severity of Graves\u2019 ophthalmopathy. Arch Intern Med. 1990;150:1098\u2013101.","journal-title":"Arch Intern Med"},{"key":"1459_CR8","doi-asserted-by":"crossref","first-page":"7010196","DOI":"10.1155\/2018\/7010196","volume":"2018","author":"N Turck","year":"2018","unstructured":"Turck N, Eperon S, De Los Angeles Gracia M, Ob\u00e9ric A, Ham\u00e9dani M. Thyroid-associated orbitopathy and biomarkers: where we are and what we can hope for the future. Dis Markers. Hindawi. 2018;2018:7010196.","journal-title":"Dis Markers"},{"key":"1459_CR9","doi-asserted-by":"crossref","first-page":"29615","DOI":"10.1074\/jbc.273.45.29615","volume":"273","author":"HJ Cao","year":"1998","unstructured":"Cao HJ, Wang HS, Zhang Y, Lin HY, Phipps RP, Smith TJ. Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression. Insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy. J Biol Chem. 1998;273:29615\u201325.","journal-title":"J Biol Chem"},{"key":"1459_CR10","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","volume":"375","author":"TJ Smith","year":"2016","unstructured":"Smith TJ, Hegedus L. Graves\u2019 disease. N Engl J Med. 2016;375:1552\u201365.","journal-title":"N Engl J Med"},{"key":"1459_CR11","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.4049\/jimmunol.170.12.6348","volume":"170","author":"J Pritchard","year":"2003","unstructured":"Pritchard J, Han R, Horst N, Cruikshank WW, Smith TJ. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves\u2019 disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol. 2003;170:6348\u201354.","journal-title":"J Immunol"},{"key":"1459_CR12","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.4049\/jimmunol.178.5.3281","volume":"178","author":"RS Douglas","year":"2007","unstructured":"Douglas RS, Gianoukakis AG, Kamat S, Smith TJ. Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves\u2019 disease may carry functional consequences for disease pathogenesis. J Immunol. 2007;178:3281\u20137.","journal-title":"J Immunol"},{"key":"1459_CR13","doi-asserted-by":"crossref","first-page":"5768","DOI":"10.4049\/jimmunol.181.8.5768","volume":"181","author":"RS Douglas","year":"2008","unstructured":"Douglas RS, Naik V, Hwang CJ, Afifiyan NF, Gianoukakis AG, Sand D, et al. B cells from patients with Graves\u2019 disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J Immunol. 2008;181:5768\u201374.","journal-title":"J Immunol"},{"key":"1459_CR14","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0002-9394(14)70276-4","volume":"121","author":"GB Bartley","year":"1996","unstructured":"Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA, et al. Clinical features of Graves\u2019 ophthalmopathy in an incidence cohort. Am J Ophthalmol. 1996;121:284\u201390.","journal-title":"Am J Ophthalmol"},{"key":"1459_CR15","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1136\/bjo.2007.137265","volume":"93","author":"AK Eckstein","year":"2009","unstructured":"Eckstein AK, L\u00f6sch C, Glowacka D, Schott M, Mann K, Esser J, et al. Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical Graves ophthalmopathy. Br J Ophthalmol. 2009;93:1052\u20136.","journal-title":"Br J Ophthalmol"},{"key":"1459_CR16","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1055\/a-0739-8134","volume":"50","author":"A Kotwal","year":"2018","unstructured":"Kotwal A, Stan M. Current and future treatments for Graves\u2019 disease and Graves\u2019 ophthalmopathy. Horm Metab Res. 2018;50:871\u201386.","journal-title":"Horm Metab Res"},{"key":"1459_CR17","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","volume":"382","author":"RS Douglas","year":"2020","unstructured":"Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EH, Perdok R, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382:341\u201352.","journal-title":"N Engl J Med"},{"key":"1459_CR18","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1089\/thy.2012.0205","volume":"22","author":"JR Garber","year":"2012","unstructured":"Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid. 2012;22:1200\u201335.","journal-title":"Thyroid."},{"key":"1459_CR19","doi-asserted-by":"crossref","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P). Syst Rev [Internet]. 2015 [cited 2020 Apr 7];4. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25554246.","DOI":"10.1186\/2046-4053-4-1"},{"key":"1459_CR20","unstructured":"ebp - Critical Appraisal Tools | Joanna Briggs Institute [Internet]. [cited 2020 Apr 7]. Available from: https:\/\/joannabriggs.org\/ebp\/critical_appraisal_tools."},{"key":"1459_CR21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/XEB.0000000000000054","volume":"13","author":"Z Munn","year":"2015","unstructured":"Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int J Evid Based Healthc. 2015;13:147\u201353.","journal-title":"Int J Evid Based Healthc"},{"key":"1459_CR22","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1038\/eye.2011.186","volume":"25","author":"MB Kashkouli","year":"2011","unstructured":"Kashkouli MB, Pakdel F, Kiavash V, Heidari I, Heirati A, Jam S. Hyperthyroid vs hypothyroid eye disease: the same severity and activity. Eye (Lond). 2011;25:1442\u20136.","journal-title":"Eye (Lond)"},{"key":"1459_CR23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4103\/0301-4738.83612","volume":"59","author":"MB Kashkouli","year":"2011","unstructured":"Kashkouli MB, Kaghazkanani R, Heidari I, Ketabi N, Jam S, Azarnia S, et al. Bilateral versus unilateral thyroid eye disease. Indian J Ophthalmol. Wolters Kluwer--Medknow Publications. 2011;59:363.","journal-title":"Indian J Ophthalmol"},{"key":"1459_CR24","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4103\/meajo.MEAJO_91_17","volume":"24","author":"E Ackuaku-Dogbe","year":"2017","unstructured":"Ackuaku-Dogbe E, Akpalu J, Abaidoo B. Epidemiology and clinical features of thyroid-associated orbitopathy in Accra. Middle East Afr J Ophthalmol. 2017;24:183\u20139.","journal-title":"Middle East Afr J Ophthalmol"},{"key":"1459_CR25","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.endonu.2012.09.002","volume":"60","author":"MRA Exp\u00f3sito","year":"2013","unstructured":"Exp\u00f3sito MRA, Moreno M\u00c1G, Moreno PM, S\u00e1nchez IP, Jim\u00e9nez CM, L\u00f3pez PB. Evaluaci\u00f3n de la efectividad del tratamiento con glucocorticoides intravenosos en la oftalmopat\u00eda de Graves. Endocrinolog\u00eda y Nutrici\u00f3n Elsevier. 2013;60:10\u20134.","journal-title":"Endocrinolog\u00eda y Nutrici\u00f3n Elsevier"},{"key":"1459_CR26","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/eye.2012.132","volume":"26","author":"SY Jang","year":"2012","unstructured":"Jang SY, Lee SY, Lee EJ, Yoon JS. Clinical features of thyroid-associated ophthalmopathy in clinically euthyroid Korean patients. Eye (Lond). 2012;26:1263\u20139.","journal-title":"Eye (Lond)"},{"key":"1459_CR27","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1089\/thy.2000.10.1093","volume":"10","author":"DH Khoo","year":"2000","unstructured":"Khoo DH, Eng PH, Ho SC, Tai ES, Morgenthaler NG, Seah LL, et al. Graves\u2019 ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels. Thyroid. 2000;10:1093\u2013100.","journal-title":"Thyroid."},{"key":"1459_CR28","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/bjo.2006.094607","volume":"91","author":"D McKeag","year":"2007","unstructured":"McKeag D, Lane C, Lazarus JH, Baldeschi L, Boboridis K, Dickinson AJ, et al. Clinical features of dysthyroid optic neuropathy: a European Group on Graves\u2019 Orbitopathy (EUGOGO) survey. Br J Ophthalmol. 2007;91:455\u20138.","journal-title":"Br J Ophthalmol"},{"key":"1459_CR29","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.joco.2018.07.001","volume":"30","author":"A Medghalchi","year":"2018","unstructured":"Medghalchi A, Akbari M, Alizadeh Y, Moghadam RS. The epidemiological characteristics of patients with thyroid eye disease in a referral center in northern Iran. J Curr Ophthalmol. 2018;30:353\u20138.","journal-title":"J Curr Ophthalmol"},{"key":"1459_CR30","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1507\/endocrj.EJ15-0137","volume":"63","author":"K Mukasa","year":"2016","unstructured":"Mukasa K, Yoshimura Noh J, Kouzaki A, Ohye H, Kunii Y, Watanabe N, et al. TSH receptor antibody titers measured with a third-generation assay did not reflect the activity of Graves\u2019 ophthalmopathy in untreated Japanese Graves\u2019 disease patients. Endocr J. 2016;63:151\u20137.","journal-title":"Endocr J"},{"key":"1459_CR31","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/cei.12395","volume":"178","author":"KA Ponto","year":"2014","unstructured":"Ponto KA, Schuppan D, Zwiener I, Binder H, Mirshahi A, Diana T, et al. Thyroid-associated orbitopathy is linked to gastrointestinal autoimmunity. Clin Exp Immunol. 2014;178:57\u201364.","journal-title":"Clin Exp Immunol"},{"key":"1459_CR32","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1089\/thy.2015.0031","volume":"25","author":"KA Ponto","year":"2015","unstructured":"Ponto KA, Binder H, Diana T, Matheis N, Otto AF, Pitz S, et al. Prevalence, phenotype, and psychosocial well-being in euthyroid\/hypothyroid thyroid-associated orbitopathy. Thyroid. 2015;25:942\u20138.","journal-title":"Thyroid."},{"key":"1459_CR33","doi-asserted-by":"crossref","unstructured":"Cozma I, Cozma L, Boyce R, Ludgate ME, Lazarus JH, Lane C. Variation in thyroid status in patients with Graves \u2019orbitopathy. Acta Endocrinologica (1841-0987). 2009;5:191\u20138.","DOI":"10.4183\/aeb.2009.191"},{"key":"1459_CR34","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1530\/EJE-11-0055","volume":"164","author":"S Estcourt","year":"2011","unstructured":"Estcourt S, Quinn AG, Vaidya B. Quality of life in thyroid eye disease: Impact of quality of care. Eur J Endocrinol Suppl. 2011;164:649\u201355.","journal-title":"Eur J Endocrinol Suppl"},{"key":"1459_CR35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40662-014-0009-8","volume":"1","author":"C McAlinden","year":"2014","unstructured":"McAlinden C. An overview of thyroid eye disease. Eye Vis (Lond). 2014;1:9.","journal-title":"Eye Vis (Lond)"},{"key":"1459_CR36","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1515\/jpem-2016-0122","volume":"29","author":"J Szczapa-Jagustyn","year":"2016","unstructured":"Szczapa-Jagustyn J, Gotz-Wieckowska A, Kociecki J. An update on thyroid-associated ophthalmopathy in children and adolescents. J Pediatr Endocrinol Metab. 2016;29:1115\u201322.","journal-title":"J Pediatr Endocrinol Metab"},{"key":"1459_CR37","volume-title":"Graves\u2019 disease","author":"I Campi","year":"2018","unstructured":"Campi I, Salvi M. Graves\u2019 disease; 2018."},{"key":"1459_CR38","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1210\/jcem-69-6-1104","volume":"69","author":"A Martin","year":"1989","unstructured":"Martin A, Schwartz AE, Friedman EW, Davies TF. Successful production of intrathyroidal human T cell hybridomas: evidence for intact helper T cell function in Graves\u2019 disease. J Clin Endocrinol Metab. 1989;69:1104\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"1459_CR39","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3109\/08916934.2015.1022163","volume":"48","author":"K Nagata","year":"2015","unstructured":"Nagata K, Nakayama Y, Higaki K, Ochi M, Kanai K, Matsushita M, et al. Reactivation of persistent Epstein-Barr virus (EBV) causes secretion of thyrotropin receptor antibodies (TRAbs) in EBV-infected B lymphocytes with TRAbs on their surface. Autoimmunity. 2015;48:328\u201335.","journal-title":"Autoimmunity."},{"key":"1459_CR40","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1172\/JCI114768","volume":"86","author":"AP Weetman","year":"1990","unstructured":"Weetman AP, Yateman ME, Ealey PA, Black CM, Reimer CB, Williams RCJ, et al. Thyroid-stimulating antibody activity between different immunoglobulin G subclasses. J Clin Invest. 1990;86:723\u20137.","journal-title":"J Clin Invest"},{"key":"1459_CR41","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1146\/annurev-pathol-012513-104713","volume":"9","author":"Y Tomer","year":"2014","unstructured":"Tomer Y. Mechanisms of autoimmune thyroid diseases: from genetics to epigenetics. Annu Rev Pathol. 2014;9:147\u201356.","journal-title":"Annu Rev Pathol"},{"key":"1459_CR42","first-page":"930","volume":"86","author":"TH Brix","year":"2001","unstructured":"Brix TH, Kyvik KO, Christensen K, Heged\u00fcs L. Evidence for a major role of heredity in Graves\u2019 disease: a population-based study of two Danish twin cohorts. J Clin Endocrinol Metabol. 2001;86:930\u20134.","journal-title":"J Clin Endocrinol Metabol"},{"key":"1459_CR43","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaut.2015.09.006","volume":"67","author":"M Limbach","year":"2016","unstructured":"Limbach M, Saare M, Tserel L, Kisand K, Eglit T, Sauer S, et al. Epigenetic profiling in CD4+ and CD8+ T cells from Graves\u2019 disease patients reveals changes in genes associated with T cell receptor signaling. J Autoimmun. 2016;67:46\u201356.","journal-title":"J Autoimmun"},{"key":"1459_CR44","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(99)02429-0","volume":"354","author":"AJ Coles","year":"1999","unstructured":"Coles AJ, Wing M, Smith S, Coraddu F, Greer S, Taylor C, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet Elsevier. 1999;354:1691\u20135.","journal-title":"Lancet"},{"key":"1459_CR45","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1089\/thy.2012.0007","volume":"22","author":"X Yin","year":"2012","unstructured":"Yin X, Latif R, Bahn R, Davies TF. Genetic profiling in Graves\u2019 disease: further evidence for lack of a distinct genetic contribution to Graves\u2019 ophthalmopathy. Thyroid. 2012;22:730\u20136.","journal-title":"Thyroid."},{"key":"1459_CR46","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1055\/s-0035-1548832","volume":"47","author":"RA Ajjan","year":"2015","unstructured":"Ajjan RA, Weetman AP. The pathogenesis of Hashimoto\u2019s thyroiditis: further developments in our understanding. Horm Metab Res. \u00a9 Georg Thieme Verlag KG. 2015;47:702\u201310.","journal-title":"Horm Metab Res"},{"key":"1459_CR47","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.autrev.2014.01.007","volume":"13","author":"P Caturegli","year":"2014","unstructured":"Caturegli P, De Remigis A, Rose N. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev Elsevier. 2014;13:391\u20137.","journal-title":"Autoimmun Rev"},{"key":"1459_CR48","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/08916934.2013.866101","volume":"47","author":"I Zaaber","year":"2014","unstructured":"Zaaber I, Mestiri S, Marmouch H, Mahjoub S, Abid N, Hassine M, et al. Polymorphisms in TSHR and IL1RN genes and the risk and prognosis of Hashimoto\u2019s thyroiditis. Autoimmunity Taylor & Francis. 2014;47:113\u20138.","journal-title":"Autoimmunity Taylor & Francis"},{"key":"1459_CR49","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1210\/jc.2016-1220","volume":"101","author":"GJ Kahaly","year":"2016","unstructured":"Kahaly GJ, Diana T, Glang J, Kanitz M, Pitz S, Konig J. Thyroid stimulating antibodies are highly prevalent in Hashimoto\u2019s thyroiditis and associated orbitopathy. J Clin Endocrinol Metab. 2016;101:1998\u20132004.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-020-01459-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-020-01459-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-020-01459-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T20:49:47Z","timestamp":1630442987000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-020-01459-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1459"],"URL":"https:\/\/doi.org\/10.1186\/s13643-020-01459-7","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,1]]},"assertion":[{"value":"8 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The present study was performed following the ethical principles for research involving human beings established by the Declaration of Helsinki, the Belmont Report, and Colombian Resolution 008430 of 1993. As it is a systematic review of the literature, it does not require approval by the ethics committee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"201"}}